Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.

Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, Murrell DF, Alexis A, Lindsey L, Ahmad F, Piketty C, Clucas A.

J Allergy Clin Immunol. 2019 Aug 23. pii: S0091-6749(19)31099-1. doi: 10.1016/j.jaci.2019.08.013. [Epub ahead of print]

2.

Different phenotypes and factors associated with atopic dermatitis in the young adult Singaporean Chinese population: A cross-sectional study.

Matta SA, Blanchet-Rethore S, Sio YY, Suri BK, Andiappan AK, Anantharaman R, Piketty C, Bourdes V, Chew FT.

World Allergy Organ J. 2019 Jan 26;12(1):100008. doi: 10.1016/j.waojou.2018.11.006. eCollection 2019.

3.

Evolution and duration of nodules in severe nodular acne on the back: results from a four-week non-interventional, prospective study.

Khammari A, Blanchet-Réthoré S, Bourdès V, Marty C, Piketty C, Dréno B.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):601-607. doi: 10.1111/jdv.15407.

PMID:
30891846
4.

Most associations of early-life environmental exposures and genetic risk factors poorly differentiate between eczema phenotypes: the Generation R Study.

Hu C, Duijts L, Erler NS, Elbert NJ, Piketty C, Bourdès V, Blanchet-Réthoré S, de Jongste JC, Pasmans SGMA, Felix JF, Nijsten T.

Br J Dermatol. 2019 Dec;181(6):1190-1197. doi: 10.1111/bjd.17879. Epub 2019 Jul 30.

PMID:
30869802
5.

A novel image processing workflow for the in vivo quantification of skin microvasculature using dynamic optical coherence tomography.

Zugaj D, Chenet A, Petit L, Vaglio J, Pascual T, Piketty C, Bourdes V.

Skin Res Technol. 2018 Aug;24(3):396-406. doi: 10.1111/srt.12442. Epub 2018 Feb 4.

PMID:
29399881
6.

A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.

Assoumou L, Weiss L, Piketty C, Burgard M, Melard A, Girard PM, Rouzioux C, Costagliola D; ANRS 116 SALTO study group.

AIDS. 2015 Sep 24;29(15):2003-7. doi: 10.1097/QAD.0000000000000734.

PMID:
26355572
7.

T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection.

Weiss L, Chevalier MF, Assoumou L, Didier C, Girard PM, Piketty C, Costagliola D, Rouzioux C; ANRS 116 SALTO Study Group.

AIDS. 2014 Jul 17;28(11):1683-7. doi: 10.1097/QAD.0000000000000319.

PMID:
24841127
8.

Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV.

Piketty C, Selinger-Leneman H, Bouvier AM, Belot A, Mary-Krause M, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Grabar S.

J Clin Oncol. 2012 Dec 10;30(35):4360-6. doi: 10.1200/JCO.2012.44.5486. Epub 2012 Oct 22.

PMID:
23091098
9.

Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART.

Piketty C, Cochand-Priollet B, Lanoy E, Si-Mohamed A, Trabelsi S, Tubiana R, Girard PM, Weiss L, Costagliola D; Valparaiso Study Group.

AIDS. 2013 Jan 28;27(3):401-6. doi: 10.1097/QAD.0b013e32835ad2cb.

PMID:
23079803
10.

Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort.

Jarzebowski W, Caumes E, Dupin N, Farhi D, Lascaux AS, Piketty C, de Truchis P, Bouldouyre MA, Derradji O, Pacanowski J, Costagliola D, Grabar S; FHDH-ANRS CO4 Study Team.

Arch Intern Med. 2012 Sep 10;172(16):1237-43.

PMID:
22826097
11.

Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study.

Mole B, Gillaizeau F, Carbonnel E, Pierre I, Brazille P, Grataloup C, Mercier S, Duracinsky M, Weiss L, Piketty C.

AIDS Res Hum Retroviruses. 2012 Mar;28(3):251-8. doi: 10.1089/AID.2011.0042. Epub 2011 Aug 30.

PMID:
21801082
12.

Knowledge of oral drug treatment in immunocompromised patients on hospital discharge.

Chau I, Korb-Savoldelli V, Trinquart L, Caruba T, Prognon P, Durieux P, Piketty C, Sabatier B.

Swiss Med Wkly. 2011 Jun 24;141:w13204. doi: 10.4414/smw.2011.13204. eCollection 2011.

13.

Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy.

Charpentier C, Piketty C, Laureillard D, Tisserand P, Si-Mohamed A, Weiss L, Bélec L.

Eur J Clin Microbiol Infect Dis. 2012 Feb;31(2):129-33. doi: 10.1007/s10096-011-1284-0. Epub 2011 May 11.

PMID:
21559766
14.

Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.

Charpentier C, Jenabian MA, Piketty C, Karmochkine M, Tisserand P, Laureillard D, Bélec L, Si-Mohamed A, Weiss L.

Scand J Infect Dis. 2011 May;43(5):373-9. doi: 10.3109/00365548.2011.552520. Epub 2011 Feb 22.

PMID:
21341978
15.

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.

Barrail-Tran A, Yazdanpanah Y, Goldwirt L, Chêne G, Colin C, Piketty C, Bollens D, Katlama C, Descamps D, Molina JM, Fagard C, Taburet AM; ANRS 139 study group.

AIDS. 2010 Oct 23;24(16):2581-3.

PMID:
20960678
16.

Murine typhus as a cause of Fever in travelers from Tunisia and mediterranean areas.

Angelakis E, Botelho E, Socolovschi C, Sobas CR, Piketty C, Parola P, Raoult D.

J Travel Med. 2010 Sep-Oct;17(5):310-5. doi: 10.1111/j.1708-8305.2010.00435.x.

17.

A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.

Piketty C, Weiss L, Assoumou L, Burgard M, Mélard A, Ragnaud JM, Bentata M, Girard PM, Rouzioux C, Costagliola D; ANRS 116 SALTO Study Group.

J Med Virol. 2010 Nov;82(11):1819-28. doi: 10.1002/jmv.21907.

PMID:
20872707
18.

Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy.

Weiss L, Piketty C, Assoumou L, Didier C, Caccavelli L, Donkova-Petrini V, Levy Y, Girard PM, Burgard M, Viard JP, Rouzioux C, Costagliola D; ANRS 116 SALTO study group.

PLoS One. 2010 Jul 21;5(7):e11659. doi: 10.1371/journal.pone.0011659.

19.

High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.

Charpentier C, Laureillard D, Piketty C, Tisserand P, Batisse D, Karmochkine M, Si-Mohamed A, Weiss L.

AIDS. 2010 Mar 27;24(6):867-73. doi: 10.1097/QAD.0b013e3283367796.

PMID:
20160635
20.

Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.

Barrail-Tran A, Mentré F, Cosson C, Piketty C, Chazallon C, Gérard L, Girard PM, Taburet AM.

Antimicrob Agents Chemother. 2010 Feb;54(2):614-9. doi: 10.1128/AAC.00797-09. Epub 2009 Dec 7.

21.

Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure.

Stegmann S, Manea ME, Charpentier C, Damond F, Karmochkine M, Laureillard D, Si-Mohamed A, Weiss L, Piketty C.

J Clin Virol. 2010 Jan;47(1):79-81. doi: 10.1016/j.jcv.2009.11.008. Epub 2009 Dec 3.

PMID:
19962343
22.

A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients.

Bouillon-Pichault M, Jullien V, Piketty C, Viard JP, Morini JP, Chhun S, Krivine A, Salmon D, Dupin N, Weiss L, Lortholary O, Pons G, Launay O, Treluyer JM.

Antivir Ther. 2009;14(7):923-9. doi: 10.3851/IMP1414.

PMID:
19918096
23.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group.

Clin Infect Dis. 2009 Nov 1;49(9):1441-9. doi: 10.1086/630210.

PMID:
19814627
24.

Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication.

Gérard L, Meignin V, Galicier L, Fieschi C, Leturque N, Piketty C, Fonquernie L, Agbalika F, Oksenhendler E.

AIDS. 2009 Nov 13;23(17):2301-8. doi: 10.1097/QAD.0b013e328330f62d.

PMID:
19752717
25.

Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.

Charpentier C, Laureillard D, Sodqi M, Si-Mohamed A, Karmochkine M, Bélec L, Weiss L, Piketty C.

J Clin Virol. 2008 Oct;43(2):212-5. doi: 10.1016/j.jcv.2008.07.001. Epub 2008 Aug 28.

PMID:
18760662
26.

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.

Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Bélec L, Weiss L, Si-Mohamed A, Piketty C.

HIV Med. 2008 Oct;9(9):765-70. doi: 10.1111/j.1468-1293.2008.00628.x. Epub 2008 Jul 21.

27.

Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.

Laureillard D, Prak N, Fernandez M, Ngeth C, Moeung S, Riel V, Chhneang V, Song S, Quillet C, Piketty C.

HIV Med. 2008 Aug;9(7):514-8. doi: 10.1111/j.1468-1293.2008.00597.x. Epub 2008 Jun 28.

28.

Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy.

Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause M; FHDH-ANRS CO 4.

AIDS. 2008 Jun 19;22(10):1203-11. doi: 10.1097/QAD.0b013e3283023f78.

PMID:
18525266
29.

Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.

Gérard L, Chazallon C, Taburet AM, Girard PM, Aboulker JP, Piketty C.

Antivir Ther. 2007;12(1):31-9.

PMID:
17503745
30.

Acquired resistance to echinocandins in Candida albicans: case report and review.

Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, Piketty C, Dannaoui E.

J Antimicrob Chemother. 2007 Jun;59(6):1076-83. Epub 2007 Apr 27.

PMID:
17468115
31.

Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial.

Ghosn J, Quinson AM, Sabo N, Cotte L, Piketty C, Dorléacq N, Bravo ML, Mayers D, Harmenberg J, Mårdh G, Valdez H, Katlama C.

HIV Med. 2007 Apr;8(3):142-7.

32.

Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene.

Si-Mohamed A, Piketty C, Tisserand P, LeGoff J, Weiss L, Charpentier C, Kazatchkine MD, Bélec L.

J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):1-5.

PMID:
17075396
33.

Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients.

Duong Van Huyen JP, Batisse D, Heudes D, Belair MF, Piketty C, Gonzalez-Canali G, Weiss L, Kazatchkine MD, Bruneval P.

Mod Pathol. 2006 Oct;19(10):1277-88. Epub 2006 Jun 30.

34.

Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient.

Touzot M, Beller CL, Touzot F, Louet AL, Piketty C.

AIDS. 2006 May 12;20(8):1210-2. No abstract available.

PMID:
16691080
35.

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel F, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM; Agence Nationale de Recherche sur le SIDA 107-Puzzle 2 Study Group.

Antivir Ther. 2006;11(2):213-21.

PMID:
16640102
36.

External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.

Marcelin AG, Chazallon C, Gérard L, Saïdi Y, Aboulker JP, Girard PM, Calvez V, Piketty C.

J Acquir Immune Defic Syndr. 2006 May;42(1):127-8. No abstract available.

PMID:
16639354
37.

Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy.

Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, Viard JP, Piketty C, Rouveix E, Rouzioux C, Weiss L, Pol S.

AIDS. 2006 Jan 9;20(2):233-40.

PMID:
16511416
38.

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C; TECOVIR Study Group.

Hepatology. 2006 Mar;43(3):548-55.

PMID:
16496322
39.
40.

High seroprevalence of herpes simplex virus type 2 infection in French human immunodeficiency virus type 1-infected outpatients.

Andréoletti L, Piednoir E, Legoff J, Brodard V, Beguinot I, Strady C, Rouger C, Piketty C, Si-Mohamed A, Kazatchkine MD, Malkin JE, Bélec L.

J Clin Microbiol. 2005 Aug;43(8):4215-7.

41.

Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures.

Piketty C, Gérard L, Chazallon C, Calvez V, Clavel F, Taburet AM, Girard PM, Aboulker JP; ANRS 107 Puzzle 2 Study Group.

AIDS. 2004 Jul 2;18(10):1469-71.

PMID:
15199325
42.

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.

Taburet AM, Piketty C, Chazallon C, Vincent I, Gérard L, Calvez V, Clavel F, Aboulker JP, Girard PM.

Antimicrob Agents Chemother. 2004 Jun;48(6):2091-6.

43.

Unusual pulmonary Enterocytozoon bieneusi microsporidiosis in an AIDS patient: case report and review.

Sodqi M, Brazille P, Gonzalez-Canali G, Cornet M, Piketty C, Weiss L.

Scand J Infect Dis. 2004;36(3):230-1. Review.

PMID:
15119373
44.

Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.

Launay O, Roudière L, Boukli N, Dupont B, Prévoteau du Clary F, Patey O, David F, Lortholary O, Devidas A, Piketty C, Rey E, Urbinelli R, Allaert FA, Tréluyer JM, Caumes E; Viramune-Zyrtec Study Group.

Clin Infect Dis. 2004 Apr 15;38(8):e66-72. Epub 2004 Mar 29.

PMID:
15095233
45.

Salivary production of IgA and IgG to human herpes virus 8 latent and lytic antigens by patients in whom Kaposi's sarcoma has regressed.

Mbopi-Keou FX, Legoff J, Piketty C, Hocini H, Malkin JE, Inoue N, Scully CM, Porter SR, Teo CG, Belec L.

AIDS. 2004 Jan 23;18(2):338-40.

PMID:
15075558
46.

High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy.

Piketty C, Darragh TM, Heard I, Da Costa M, Bruneval P, Kazatchkine MD, Palefsky JM.

Sex Transm Dis. 2004 Feb;31(2):96-9.

PMID:
14743072
47.

Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy.

Duong Van Huyen JP, Landau A, Piketty C, Bélair MF, Batisse D, Gonzalez-Canali G, Weiss L, Jian R, Kazatchkine MD, Bruneval P.

Am J Clin Pathol. 2003 Apr;119(4):546-55.

PMID:
12710127
48.

Renal lesions in HIV-1-positive patient treated with tenofovir.

Créput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D.

AIDS. 2003 Apr 11;17(6):935-7. No abstract available.

PMID:
12660548
49.

High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse.

Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, Palefsky JM.

Ann Intern Med. 2003 Mar 18;138(6):453-9.

PMID:
12639077
50.

Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz.

Piketty C, Peytavin G, Trylezinski A, Gonzalez-Canali G, Castiel P, Weiss L, Kazatchkine MD.

HIV Med. 2002 Oct;3(4):287-9. No abstract available.

Supplemental Content

Loading ...
Support Center